Insider · CIK 0001715153
James Arthur Bristol
director
Files at ERNA (Ernexa Therapeutics Inc.), ERAS (Erasca, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | ERNA Ernexa Therapeutics Inc. | AGrant or award Stock Option (Right to buy)derivative | +8,320 | $0.00 | $0 | 8,320 | 41 d ago |
| Aug 31, 2026 | ERNA Ernexa Therapeutics Inc. | AGrant or award Stock Option (Right to buy)derivative | +5,083 | $0.00 | $0 | 5,083 | 41 d ago |
| Jun 24, 2025 | ERAS Erasca, Inc. | AGrant or award Stock option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Jun 26, 2025 |
| Feb 7, 2025 | ERNA Ernexa Therapeutics Inc. | AGrant or award Stock Option (Right to buy)derivative | +72,074 | $0.00 | $0 | 72,074 | Feb 10, 2025 |
| Jan 1, 2025 | ERAS Erasca, Inc. | AGrant or award Stock Option (right to buy)derivative | +45,678 | $0.00 | $0 | 45,678 | Jan 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.